These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34333045)

  • 1. Loss-of-function mutations in BCOR contribute to chemotherapy resistance in acute myeloid leukemia.
    Honda A; Koya J; Yoshimi A; Miyauchi M; Taoka K; Kataoka K; Arai S; Kurokawa M
    Exp Hematol; 2021 Sep; 101-102():42-48.e11. PubMed ID: 34333045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype.
    Grossmann V; Tiacci E; Holmes AB; Kohlmann A; Martelli MP; Kern W; Spanhol-Rosseto A; Klein HU; Dugas M; Schindela S; Trifonov V; Schnittger S; Haferlach C; Bassan R; Wells VA; Spinelli O; Chan J; Rossi R; Baldoni S; De Carolis L; Goetze K; Serve H; Peceny R; Kreuzer KA; Oruzio D; Specchia G; Di Raimondo F; Fabbiano F; Sborgia M; Liso A; Farinelli L; Rambaldi A; Pasqualucci L; Rabadan R; Haferlach T; Falini B
    Blood; 2011 Dec; 118(23):6153-63. PubMed ID: 22012066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of BCOR gene mutation as a prognostic factor in acute myeloid leukemia with intermediate cytogenetic prognosis.
    Terada K; Yamaguchi H; Ueki T; Usuki K; Kobayashi Y; Tajika K; Gomi S; Kurosawa S; Saito R; Furuta Y; Miyadera K; Tokura T; Marumo A; Omori I; Sakaguchi M; Fujiwara Y; Yui S; Ryotokuji T; Arai K; Kitano T; Wakita S; Fukuda T; Inokuchi K
    Genes Chromosomes Cancer; 2018 Aug; 57(8):401-408. PubMed ID: 29663558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders.
    Damm F; Chesnais V; Nagata Y; Yoshida K; Scourzic L; Okuno Y; Itzykson R; Sanada M; Shiraishi Y; Gelsi-Boyer V; Renneville A; Miyano S; Mori H; Shih LY; Park S; Dreyfus F; Guerci-Bresler A; Solary E; Rose C; Cheze S; Prébet T; Vey N; Legentil M; Duffourd Y; de Botton S; Preudhomme C; Birnbaum D; Bernard OA; Ogawa S; Fontenay M; Kosmider O
    Blood; 2013 Oct; 122(18):3169-77. PubMed ID: 24047651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
    Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
    Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-Related Co-Expression of BCOR and BCORL1 mRNA in Acute Myeloid Leukemia.
    Coskun FR; Percin-Pacal F; Emrence Z; Ar MC; Abaci N; Unuvar A; Eskazan AE; Elverdi T; Salihoglu A; Seflekci Y; Karakas Z; Soysal T; Sirma-Ekmekci S
    Clin Lab; 2020 Aug; 66(8):. PubMed ID: 32776737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCOR and BCORL1 mutations in pediatric acute myeloid leukemia.
    de Rooij JD; van den Heuvel-Eibrink MM; Hermkens MC; Verboon LJ; Arentsen-Peters ST; Fornerod M; Baruchel A; Stary J; Reinhardt D; de Haas V; Pieters R; Zwaan CM
    Haematologica; 2015 May; 100(5):e194-5. PubMed ID: 25596268
    [No Abstract]   [Full Text] [Related]  

  • 8. Clarifying the impact of polycomb complex component disruption in human cancers.
    Yamamoto Y; Abe A; Emi N
    Mol Cancer Res; 2014 Apr; 12(4):479-84. PubMed ID: 24515802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.
    Kontro M; Kumar A; Majumder MM; Eldfors S; Parsons A; Pemovska T; Saarela J; Yadav B; Malani D; Fløisand Y; Höglund M; Remes K; Gjertsen BT; Kallioniemi O; Wennerberg K; Heckman CA; Porkka K
    Leukemia; 2017 Feb; 31(2):301-309. PubMed ID: 27499136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole exome sequencing identifies novel mutations of epigenetic regulators in chemorefractory pediatric acute myeloid leukemia.
    Zhan D; Zhang Y; Xiao P; Zheng X; Ruan M; Zhang J; Chen A; Zou Y; Chen Y; Huang G; Hu S; Wang QF; Zhu X
    Leuk Res; 2018 Feb; 65():20-24. PubMed ID: 29253671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant U2AF1-Induced Mis-Splicing of mRNA Translation Genes Confers Resistance to Chemotherapy in Acute Myeloid Leukemia.
    Jin P; Wang X; Jin Q; Zhang Y; Shen J; Jiang G; Zhu H; Zhao M; Wang D; Li Z; Zhou Y; Li W; Zhang W; Liu Y; Wang S; Jin W; Cao Y; Sheng G; Dong F; Wu S; Li X; Jin Z; He M; Liu X; Chen L; Zhang Y; Wang K; Li J
    Cancer Res; 2024 May; 84(10):1583-1596. PubMed ID: 38417135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Relationship between ASXL2 and ZBTB7A Gene Mutations and Prognosis in Patients with Acute Myeloid Leukemia].
    Cao HQ; Tuo JB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Apr; 29(2):450-455. PubMed ID: 33812414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic biomarkers of drug resistance: A compass of prognosis and targeted therapy in acute myeloid leukemia.
    Long L; Assaraf YG; Lei ZN; Peng H; Yang L; Chen ZS; Ren S
    Drug Resist Updat; 2020 Sep; 52():100703. PubMed ID: 32599434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.
    Shiba N; Yoshida K; Shiraishi Y; Okuno Y; Yamato G; Hara Y; Nagata Y; Chiba K; Tanaka H; Terui K; Kato M; Park MJ; Ohki K; Shimada A; Takita J; Tomizawa D; Kudo K; Arakawa H; Adachi S; Taga T; Tawa A; Ito E; Horibe K; Sanada M; Miyano S; Ogawa S; Hayashi Y
    Br J Haematol; 2016 Nov; 175(3):476-489. PubMed ID: 27470916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamics of epigenetic regulator gene BCOR mutation and response predictive value for hypomethylating agents in patients with myelodysplastic syndrome.
    Li X; Xu F; Zhang Z; Guo J; He Q; Song LX; Wu D; Zhou LY; Su JY; Xiao C; Chang CK; Wu LY
    Clin Epigenetics; 2021 Aug; 13(1):169. PubMed ID: 34461985
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations.
    Lindsley RC; Mar BG; Mazzola E; Grauman PV; Shareef S; Allen SL; Pigneux A; Wetzler M; Stuart RK; Erba HP; Damon LE; Powell BL; Lindeman N; Steensma DP; Wadleigh M; DeAngelo DJ; Neuberg D; Stone RM; Ebert BL
    Blood; 2015 Feb; 125(9):1367-76. PubMed ID: 25550361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199.
    Naqvi K; Konopleva M; Ravandi F
    Expert Rev Hematol; 2017 Oct; 10(10):863-874. PubMed ID: 28799432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of nonleukemic cellular subcompartments reconstructs clonal evolution of acute myeloid leukemia and identifies therapy-resistant preleukemic clones.
    Saeed BR; Manta L; Raffel S; Pyl PT; Buss EC; Wang W; Eckstein V; Jauch A; Trumpp A; Huber W; Ho AD; Lutz C
    Int J Cancer; 2021 Jun; 148(11):2825-2838. PubMed ID: 33411954
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia.
    Zhang W; Konopleva M; Shi YX; McQueen T; Harris D; Ling X; Estrov Z; Quintás-Cardama A; Small D; Cortes J; Andreeff M
    J Natl Cancer Inst; 2008 Feb; 100(3):184-98. PubMed ID: 18230792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.